{
    "organizations": [],
    "uuid": "bdfc89cf5f0c95e21a4075d234f5d59a2fa1a895",
    "author": "",
    "url": "https://www.reuters.com/article/brief-eisai-co-merck-announce-oncology-c/brief-eisai-co-merck-announce-oncology-collaboration-for-lenvima-idUSFWN1QP0XU",
    "ord_in_thread": 0,
    "title": "BRIEF-Eisai Co, Merck Announce Oncology Collaboration For Lenvima",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 7, 2018 / 10:40 PM / Updated 11 minutes ago BRIEF-Eisai Co, Merck Announce Oncology Collaboration For Lenvima Reuters Staff March 7 (Reuters) - Eisai Co Ltd: * EISAI CO., LTD. AND MERCK ENTER GLOBAL STRATEGIC ONCOLOGY COLLABORATION FOR LENVIMA® (LENVATINIB MESYLATE) * MERCK & CO - CO, ‍​ISAI TO DEVELOP AND COMMERCIALIZE LENVIMA JOINTLY, BOTH AS MONOTHERAPY AND IN COMBINATION WITH MERCK’S ANTI-PD-1 THERAPY, KEYTRUDA * MERCK & CO INC - GROSS PROFITS FROM LENVIMA PRODUCT SALES GLOBALLY WILL BE SHARED EQUALLY BY EISAI AND MERCK * MERCK & CO - EXPENSES INCURRED DURING CO-DEVELOPMENT, INCLUDING FOR STUDIES EVALUATING LENVIMA AS MONOTHERAPY, TO BE SHARED EQUALLY BY CO, EISAI * MERCK - TO PAY EISAI UPFRONT PAYMENT OF $300 MILLION U.S. DOLLARS AND UP TO $650 MILLION U.S. DOLLARS FOR CERTAIN OPTION RIGHTS THROUGH 2020 AS PER DEAL * MERCK - TO ALSO PAY EISAI $450 MILLION AS REIMBURSEMENT FOR RESEARCH AND DEVELOPMENT EXPENSES AS PER DEAL * MERCK & CO INC - EISAI IS ELIGIBLE TO RECEIVE MAXIMUM OF UP TO $3.97 BILLION FOR ACHIEVEMENT OF MILESTONES ASSOCIATED WITH SALES OF LENVIMA * MERCK - AS PER DEAL, ‍EISAI IS ELIGIBLE TO RECEIVE UP TO $385 MILLION ASSOCIATED WITH ACHIEVEMENT OF CERTAIN CLINICAL AND REGULATORY MILESTONES​ * MERCK & CO - ASSUMING ACHIEVEMENT OF ALL GOALS FOR ALL INDICATIONS AS PER DEAL, TOTAL AMOUNT OF PAYMENTS TO EISAI COULD REACH UP TO $5.76 BILLION Source text for Eikon: Further company coverage:",
    "published": "2018-03-08T00:37:00.000+02:00",
    "crawled": "2018-03-08T00:54:43.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "co",
        "merck",
        "announce",
        "oncology",
        "collaboration",
        "lenvima",
        "reuters",
        "staff",
        "march",
        "reuters",
        "eisai",
        "co",
        "ltd",
        "eisai",
        "merck",
        "enter",
        "global",
        "strategic",
        "oncology",
        "collaboration",
        "lenvatinib",
        "mesylate",
        "merck",
        "co",
        "co",
        "develop",
        "commercialize",
        "lenvima",
        "jointly",
        "monotherapy",
        "combination",
        "merck",
        "therapy",
        "keytruda",
        "merck",
        "co",
        "inc",
        "gross",
        "profit",
        "lenvima",
        "product",
        "sale",
        "globally",
        "shared",
        "equally",
        "eisai",
        "merck",
        "merck",
        "co",
        "expense",
        "incurred",
        "including",
        "study",
        "evaluating",
        "lenvima",
        "monotherapy",
        "shared",
        "equally",
        "co",
        "eisai",
        "merck",
        "pay",
        "eisai",
        "upfront",
        "payment",
        "million",
        "dollar",
        "million",
        "dollar",
        "certain",
        "option",
        "right",
        "per",
        "deal",
        "merck",
        "also",
        "pay",
        "eisai",
        "million",
        "reimbursement",
        "research",
        "development",
        "expense",
        "per",
        "deal",
        "merck",
        "co",
        "inc",
        "eisai",
        "eligible",
        "receive",
        "maximum",
        "billion",
        "achievement",
        "milestone",
        "associated",
        "sale",
        "lenvima",
        "merck",
        "per",
        "deal",
        "eligible",
        "receive",
        "million",
        "associated",
        "achievement",
        "certain",
        "clinical",
        "regulatory",
        "merck",
        "co",
        "assuming",
        "achievement",
        "goal",
        "indication",
        "per",
        "deal",
        "total",
        "amount",
        "payment",
        "eisai",
        "could",
        "reach",
        "billion",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}